Clinical Trials

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

The U.S. Food and Drug Administration has released a draft guidance outlining safety assessment standards for human gene therapy products that incorporate genome editing technologies, marking a step toward streamlining development pathways for advanced therapies. Announced on April 14,...

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.

Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.

Examining the shift from transactional outsourcing to collaborative alliances, where shared risk and integrated data drive clinical success in the 2026 pharmaceutical landscape.

Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with...